Creating Equitable Access
To catalyze equitable access to
medicines & devices through
product development, policy advocacy,
and collaboration with U.S. and
As a nonprofit pharmaceutical organization focused on women’s health, Medicines360 is committed to developing products that enable more access for women by:
Identifying gaps through research and analysis
Conducting pharmaceutical development to bring new products to market
Leveraging philanthropic investment
Our longstanding commitment to addressing unmet needs in healthcare by working alongside stakeholders and providers is also reflected in the work we do through our subsidiary, Curae Pharma360 Inc, which is focused on improving the availability of quality generic drugs and other medicines that are in short supply.
Research into unmet needs in women’s health, developing new products, and collaborating with values-driven organizations are central to advancing our work.
As a mission-driven nonprofit pharmaceutical organization, we are passionate about leveraging science to develop effective medicines and devices that close access gaps for women around the world. Our highly skilled team of scientists, regulatory experts, clinicians, and public sector engagement associates are dedicated to not only bringing products to market, but also ensuring that women have equitable access to our products in the U.S. and globally.
Conducted the United States’ largest &
diverse Phase 3 clinical trial ever on a hormonal intrauterine device (IUD)
Made our hormonal IUD available to more than
women throughout the United States
publicly funded clinics throughout the U.S.
Saved the U.S. public healthcare system an estimated
Medicines360, through its wholly owned subsidiary Impact RH360, is working to make our hormonal IUD available in Africa, South and Southeast Asia, and Central America and the Caribbean under the brand name Avibela™.
* As of November 2022
For more product information, visit Avibela.com
Healthcare Access is Essential
Medicines360 is committed to helping bridge gaps in women’s health.
To ensure that we’re filling unmet product development needs, we actively conduct research among U.S. women and healthcare providers to understand the evolving experience of accessing healthcare.
We have found that:
Roughly 15 million
Sign up for our quarterly e-newsletter focused on improving women’s health.
We give you many choices regarding our use and disclosure of your Personal Information for marketing purposes. You may opt out from:
- Receiving marketing-related emails from us: If you no longer want to receive marketing-related emails from us on a going-forward basis, you may opt out of receiving these marketing-related emails by following the instructions included in email communications from us, or contact us at: email@example.com.
- Our sharing of your Personal Information with affiliates for their marketing purposes: If you would prefer that we do not share your Personal Information on a going-forward basis with our affiliates for their marketing purposes, you may opt out of this sharing by notifying us sending us a written statement to: Medicines360 Website, 49 Stevenson St | Suite 1100 | San Francisco, CA 94105 USA, by following the instructions included in email communication you received from us, or by contacting us at: firstname.lastname@example.org.
- Kaiser Family Foundation. Women’s Health Insurance Coverage. Accessed June 2022
- The Lancet. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019. Accessed August 2022